Hikma Delivers Strong Trading Update For 2025, Predicts Growth Across All Business Segments

Hikma Pharmaceuticals is a multinational pharmaceutical company. It provided a positive trading update before its Annual General Meeting, highlighting strong performance across its Injectables, Branded, and Generics divisions. In Injectables, revenue growth is driven by solid demand in Europe and MENA, recent launches such as liraglutide in North America, and the acquisition of Xellia’s portfolio. The company also enhances its Bedford, Ohio site to boost U.S. production capacity. Full-year Injectables revenue is expected to grow 7% to 9%, with a core operating margin in the mid-30% range.

Riad Mishlawi, Hikma’s CEO, said, “We are pleased to reiterate our Group guidance for 2025. As a global company with strong local expertise and footprint, we are leveraging our manufacturing proficiency and advanced technologies to meet the needs of our customers and patients across our markets. Looking ahead, and recognising the broader geo-political challenges, we are well-positioned. Our step up in R&D investment, alongside local manufacturing enhancements, and strategic partnerships will continue to strengthen our portfolio and pipeline and ensure sustained success.”

The Branded segment experiences continuous growth because of increased demand for chronic disease therapies and its strategic collaboration deals. Hikma reached an exclusive agreement with Austrian pharmaceutical company pharmaand GmbH to distribute oncology drug rucaparib in the MENA regions following its oncology growth strategy. The company expects Branded revenue growth to reach 6% to 7% in constant currency by 2025, and the core EBIT margin will approach 25%.

Generics are seeing stable demand, particularly for nasal and inhalation products. R&D capabilities are being strengthened with a new centre in Zagreb and upgrades at the Columbus facility to support new manufacturing partnerships. Revenue for the segment is projected to remain flat in 2025, with a 16% core operating margin. Despite global trade uncertainties, Hikma’s strong U.S. manufacturing base and diverse supply chain support its stability. The Group expects overall 2025 revenue growth of 4% to 6%, and operating profit between $730M and $770M, with a final 2024 dividend of 80 cents per share, up 11% year-over-year.